Tuesday, May 14, 2024
5/14/2024
ABSTRACT T-cell large granular lymphocytic leukemia (T-LGLL) is an incurable, underdiagnosed proliferation of clonal CD8+ cytotoxic T-lymphocytes that results in severe neutropenia and anemia, with resultant recurring infections, transfusion dependence, and death. There are no FDA-approved therapies for T-LGLL, and current immune- suppressive based therapies have marginal efficacy. Even if a response is attained with current therapies, patients shift between immune-suppressive agents, are subject to the adverse effects of these drugs, and for those with any effect, indefinite therapy is required. Urgent investigation into the pathogenesis of T-LGLL and development of rational, targeted therapies are needed. T-LGLL is a cytokine-dependent disease, driven by interleukin-15 (IL-15) which has been identified as the ‘master switch’ crucial to induce and potentiate T-LGLL. IL-15 induces pathogenesis in T-LGLL through up-regulation of STAT3, with resultant decrease in Fas/Fas- Ligand mediated apoptosis with resultant T-LGLL proliferation and cytopenias. We evaluated BNZ-1, a ¿c-inhibiting peptide that blocks IL-15, in patients with T-LGLL in only the second major, multicenter trial completed in T-LGLL. Clinical responses were observed in 20% of patients, but in vivo data revealed that nearly all patients had dramatic apoptosis of T-LGLL cells 24 hours post-BNZ-1, though apoptosis persisted only in responding patients at day 29. These results (in revision, Blood), provide in vivo proof that BNZ-1 induces T- LGLL cell apoptosis, and that T-LGLL cells are dependent on IL-15 in vivo in patients. To evaluate the mechanisms of resistance to IL-15 deprivation induced cell death, we performed single-cell RNA sequencing (scRNAseq) on samples from a non-responder. We identified the emergence of unique T-LGLL sub-populations on day 29, with corresponding up-regulation of anti-apoptotic pathways PI3K and NF-kB; implicating up- regulation of these alternate pathways in T-LGLL as key mechanisms of resistance of T-LGLL to IL-15 deprivation. Yet, validation in a larger sample set is needed to confirm these findings and identify therapeutic targets. To address these translational and clinical gaps, we will perform scRNAseq and single-cell T-cell receptor sequencing (scTCRseq) on remaining clinically annotated samples from 3 responders and 3 non- responders from the BNZ-1 trial to test our hypothesis that resistance to IL-15 deprivation with BNZ-1 is caused by expansion of resistant T-LGLL populations with upregulation of anti-apoptotic pathways (e.g. NF-kB, PI3K). In Aim 1, we will perform scRNAseq at serial timepoints (baseline, 24 hours post-BNZ-1, 29 days post BNZ-1), to identify key anti-apoptotic pathways, genes, and therapeutic targets in resistant populations. In Aim 2, we will apply scTCRseq to evaluate T-LGLL clonal populations (clonotypes), and determine the impact of IL-15 deprivation on gene expression and anti-apoptotic pathways in these groups. Upon completion, we will gain crucial mechanistic insights on the critical genes and anti-apoptotic pathways in T-LGLL that lead to resistance to IL-15 deprivation and identify therapeutic targets for a future NCI R01 proposal and BNZ-1 combinatorial trial.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
